MedTrace Logo

Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults

NCT00109746 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2016-03-23

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of the nutritional supplement chromium picolinate in improving insulin resistance, a symptom of diabetes, in HIV-infected patients. The ultimate goal is to find a simple therapy that can prevent the development of diabetes in individuals with HIV.

Conditions

Interventions

DIETARY_SUPPLEMENT

chromium picolinate

HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.

Sponsors & Collaborators

  • Office of Dietary Supplements (ODS)

    collaborator NIH

  • National Center for Complementary and Integrative Health (NCCIH)

    lead NIH

Principal Investigators

  • Marie C. Gelato, MD, PhD · State University of New York/General Clinical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2009-05-31
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00109746 on ClinicalTrials.gov